REGISTRIES. Licensee certifies that she/he is currently not listed, and has never been listed, on any state, district, commonwealth or territory sex offender registry. If Licensee is not a resident of the United States of America or its territories or commonwealths, Licensee has not been convicted of any sexual offenses that are punishable by the laws of the State of New York if the offenses had taken place within the State of New York. I have not been listed on any state, district, commonwealth or territory sex offender registry or have not been convicted of any sexual offenses that are punishable by the laws of the State of New York if the offenses had taken place in the State of New York. I certify the above to be true. (Initial Here)
REGISTRIES. Licensee certifies that she/he is currently not listed, and has never been listed, on any state, district, commonwealth or territory sex offender registry. If Licensee is not a resident of the United States of America or its territories or commonwealths, Licensee has not been convicted of any sexual offenses that are punishable by the laws of the State of New York if the offenses had taken place within the State of New York. I have not been listed on any state, district, commonwealth or territory sex offender registry or have not been convicted of any sexual offenses that are punishable by the laws of the State of New York if the offenses had taken place in the State of New York. I certify the above to be true. (Initial Here) 32. FELONY. Licensee has not been previously convicted of a felony. I have not been convicted of any felony. I certify the above to be true. (Initial Here)
REGISTRIES. Each Party shall be free to disclose any clinical trial Data generated by such Party concerning the Licensed Product as required by Applicable Law in clinical trial registries; provided, however, that the Party proposing to make such Confidential Treatment Requested disclosure shall have provided the other Party at least ** prior to such disclosure (to the extent practicable), a detailed description of the proposed disclosure and shall have, in good faith, considered the comments made by the other Party.
REGISTRIES. Licensee certifies that she/he is currently not listed, and has never been listed, on any state, district, commonwealth or territory sex offender registry. If Licensee is not a resident of the United States of America or its territories or commonwealths, Licensee has not been convicted of any sexual offenses that are punishable by the laws of the State of New York if the offenses had taken place within the State of New York. Licensee certifies the above Section 32 to be true. (INITIAL HERE)
REGISTRIES. Each Party shall be free to (a) register/publish the Clinical Studies they are sponsoring with respect to the Product, and (b) disclose any Data from such registered Clinical Trials concerning the Product, in each case on XxxxxxxxXxxxxx.xxx or in similar clinical trial registries; provided, however, that the Party proposing to make such disclosure shall have provided the other Party a copy of the synopsis of the Clinical Study or a detailed description of any other proposed disclosure, as applicable, that it proposes to have published in such clinical trial registry at least thirty (30) days prior to such registration or disclosure and shall, in good faith, consider the comments made by the other Party regarding the proposed registration or disclosure and the protection of any intellectual property contained therein.
REGISTRIES. Each Party shall be free to disclose any Clinical Study Data generated by such Party concerning the Collaboration Product in clinical trial registries, in accordance with applicable Laws; provided, however, except to the extent prohibited or otherwise required by applicable Law (and in any event consistent with applicable Law), that the Party proposing to make such disclosure shall have provided the other Party at least [***] Business Days prior to such disclosure (to the extent practicable), a detailed description of the proposed disclosure and shall have, in good faith, considered the comments made by the other Party and to delay, upon written request from the other Party, such disclosure by up to [***] days (or as long as permitted, if less than [***] days) where need to file a patent application.
REGISTRIES. Genzyme shall have the responsibility for conducting the MPS-I registry program as it exists on the Effective Date at Genzyme’s sole expense. In the event that the scope of the registry program is expanded to implement any Post-Marketing Studies required by regulatory authorities to be conducted through or as part of the registry program, such costs above the general cost of maintaining the registry program as currently conducted will be funded by BioMarin/Genzyme LLC pursuant to the terms of the Amended and Restated Collaboration Agreement.
REGISTRIES. Each Party shall be free to disclose any Clinical Study Data generated by such Party concerning the Product in clinical trial registries, in accordance with applicable Laws; provided, however, except to the extent prohibited or otherwise required by applicable Law (and in any event consistent with applicable Law), that the Party proposing to Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED Confidential make such disclosure shall have provided the other Party at least [***] Business Days prior to such disclosure (to the extent practicable), a detailed description of the proposed disclosure and shall have, in good faith, considered the comments made by the other Party and to delay, upon written request from the other Party, such disclosure by up to [***] (or as long as permitted, if less than [***] where need to file a patent application.
REGISTRIES. Each Party shall be free to disclose any Clinical Study Data generated by such Party concerning the Product in clinical trial registries, in accordance with applicable Laws; provided, however, except to the extent prohibited or otherwise required by applicable Law (and in any event consistent with applicable Law), that the Party proposing to make such disclosure shall have provided the other Party at least [***] Business Days prior to such disclosure (to the extent practicable), a detailed description of the proposed disclosure and shall have, in good faith, considered the comments made by the other Party and to delay, upon written request from the other Party, such disclosure by up to [***] (or as long as permitted, if less than [***] where need to file a patent application. 100 Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED
